Humacyte (HUMA) Net Shares Issued and Repurchased (2025 - 2026)
Humacyte's (HUMA) quarterly Net Shares Issued and Repurchased came in at $893265.0 in Q1 2026, down 90.9% quarter-over-quarter from $9.8 million in Q4 2025.
Powered by 
Analysis
Humacyte (HUMA) Net Shares Issued and Repurchased (2025 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Net Shares Issued and Repurchased for 2 consecutive years, with $893265.0 the latest figure, recorded in Q1 2026.
- On a quarterly basis, Net Shares Issued and Repurchased changed N/A year-over-year to $893265.0 in Q1 2026; TTM through Mar 2026 was $893265.0, a N/A change from a year earlier, with the FY2025 full-year figure at $9.8 million, changed N/A from the prior year.
- Net Shares Issued and Repurchased was $893265.0 for Q1 2026 at Humacyte, down from $9.8 million in the prior quarter.
- Over five years, Net Shares Issued and Repurchased peaked at $9.8 million in Q4 2025 and troughed at $893265.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.02 Bn | 5.02 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.34 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.53 Bn | 2.57 Bn | 251.50 Mn | - |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 2.53 Bn | 2.53 Bn | - | - |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn | - |
| 9 | Vericel | 1.93 Bn | 1.76 Bn | 56.40 Mn | - |
| 10 | Humacyte | 133.72 Mn | 133.72 Mn | -825,000.00 | - |